ライフサイエンスコーパス: motor complication

1 ith the development of potentially disabling motor complications.

2 be initiated first to avoid levodopa-related motor complications.

3 n's disease who have severe levodopa-induced motor complications.

4 patients with Parkinson's disease and early motor complications.

5 o delay the appearance and the extent of the motor complications.

6 in delaying the appearance and the extent of motor complications.

7 n stimulation becomes necessary to alleviate motor complications.

8 ease and to play a role in the occurrence of motor complications.

9 for the use of levodopa is the emergence of motor complications.

10 ns and surgeons who are able to handle these motor complications.

11 n of a dopaminergic drug reduces the risk of motor complications.

12 patterns in basal ganglia neurons leading to motor complications.

13 a that provides clinical benefits but avoids motor complications.

14 will prevent pulsatile stimulation and avoid motor complications.

15 n of dopamine receptors with reduced risk of motor complications.

16 effective treatment for the disease without motor complications.

17 therapy alone for patients with PD and early motor complications.

18 everse motor deficits and reduce the risk of motor complications.

19 trategies that reduce the risk of developing motor complications.

20 nger patients who have a higher incidence of motor complications.

21 vor the appearance of parkinsonian signs and motor complications.

22 control of advanced Parkinson's disease with motor complications.

23 alanine (L-DOPA)-induced dyskinesia (LID), a motor complication affecting Parkinson's disease patient

24 llness, chronic treatment is associated with motor complications and development of features that do

25 mergence of increasingly severe drug-induced motor complications and harmful behavioural consequences

26 rategies to delay and treat levodopa-related motor complications and nonmotor Parkinson's disease-rel

27 attempt to reduce or delay the appearance of motor complications and other adverse events.

28 arkinson disease, illustrates these emerging motor complications and the manner in which they may be

29 apies; however, long-term treatment leads to motor complications and, occasionally, impulse control d

30 Levodopa-induced motor complications are a common source of disability fo

31 Evidence suggests that motor complications are associated with non-physiologica

32 Experimental studies suggest that motor complications are due to non-physiological, interm

33 opment and maintenance of these drug-induced motor complications are not well understood.

34 activities of daily living, levodopa-induced motor complications (as assessed with the use of the Uni

35 advanced disease, has been characterized by motor complication, as well as by the potential emergenc

36 The motor complications associated with levodopa therapy, na

37 years) with advanced Parkinson's disease and motor complications at 26 centres in Germany, New Zealan

38 native initial therapy to delay the onset of motor complications but at the expense of more dopaminer

39 tion in Parkinson's disease with established motor complications, but rigorous studies, although expe

40 Dyskinesia, a motor complication caused by prolonged administration of

41 However, its efficacy wanes over time as motor complications develop.

42 levodopa and younger patients had developed motor complications earlier, and patients who had starte

43 intment has been the development of aberrant motor complications following dopamine (DA) neuron graft

44 n; however, in animal studies, a decrease in motor complications has been reported in drug-naive anim

45 Once motor complications have developed, adjuvant therapy wit

46 o delay the onset and reduce the severity of motor complications in MPTP monkeys and PD patients.

47 mising approach to decreasing L-DOPA-induced motor complications in Parkinson's disease.

48 levodopa may be the price for a low rate of motor complications in patients with Parkinson's disease

49 are underway to address the hypothesis that motor complications in PD can be delayed if entacapone i

50 loss of putamen dopamine storage predisposes motor complications in PD, it cannot be the only factor

51 herapy is associated with the development of motor complications in the majority of Parkinson's disea

52 With long-term use, levodopa causes motor complications including involuntary movements and

53 ing new therapeutic targets for limiting the motor complications induced by l-DOPA therapy.

54 patients with Parkinson's disease and early motor complications (mean age, 52 years; mean duration o

55 motor and nonmotor features (motor severity, motor complications, motor subtypes, quantitative motor

56 (l-DOPA)-induced dyskinesia (LID), a common motor complication of current pharmacotherapy of Parkins

57 TN) deep brain stimulation (DBS) can improve motor complications of Parkinson's disease (PD) but may

58 pted treatment for patients experiencing the motor complications of Parkinson's disease (PD).

59 ll aid the future treatment of motor and non-motor complications of Parkinson's disease.

60 functioning, while delaying or ameliorating motor complications of treatment, providing psychologica

61 of daily living (P<0.001), levodopa-induced motor complications (P<0.001), and time with good mobili

62 also been used to study processes underlying motor complications, particularly dyskinesia, and for de

63 dication was associated with higher rates of motor complications, poor or moderate response was assoc

64 Parkinson's disease (PD) patients with motor complications show a greater reduction in putamen

65 use of levodopa is commonly associated with motor complications such as dyskinesia, and both the dos

66 Non-motor complications, such as cognitive, psychiatric and

67 ges occurring in a rodent model of the human motor complication syndrome.

68 a produces many of the features of the human motor complication syndrome.

69 The most feared were the cognitive and motor complications termed AIDS dementia complex or HIV-

70 long-term utility of the drug is limited by motor complications, the development of features such as

71 However, motor complications uniquely related to levodopa treatme

72 luded activities of daily living (UPDRS-II), motor complications (UPDRS-IV), neuropsychological and s